Clinical research
The goal of the trial was to evaluate the efficacy and safety of the drug in patients six years of age and older with SCD who were hospitalized for a vaso-occlusive crisis and required treatments with intravenous opioids.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
An experimental vaccine for respiratory syncytial virus (RSV) showed positive results in a Phase I clinical trial. Researchers from The University of Texas at Austin and others reported that a single dose of the vaccine produced significant evidence of RSV-neutralizing antibodies that were sustained for several months.
Amicus Therapeutics announced positive interim results from its CLN6 Batten disease gene therapy program. Batten disease is a fatal neurologic illness that results in children losing the ability to walk, speak, think and see.
AZTherapies, Inc. announced that it has completed target enrollment in its COGNITE Phase 3 clinical trial, evaluating the safety and efficacy of ALZT-OP1 for the treatment of early Alzheimer’s disease.
Clinically advanced vaccine, ACI-35.030, designed to reduce and to prevent the spread and development of Tau pathology
Novartis announced that its Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit its key secondary endpoint, overall survival, in a pre-planned interim analysis.
Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced an oral presentation will be given at the 28th EADV Congress.
Atlantic Healthcare plc, a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases, announced the results of the Phase 3 trial of Camligo™ for orphan-designated pouchitis.
Daiichi Sankyo Europe GmbH announced that results from the 12-week, pivotal Phase 3 bempedoic acid / ezetimibe FDC tablet study (also known as Study 053) were published in the European Journal of Preventative Cardiology.
PRESS RELEASES